Dopamine signaling: nootropics and compounds | sci-wiki

Modafiendz

Modafiendz is a fluorinated, N-methylated analog of the wakefulness agent modafinil, marketed online as a next-generation nootropic alternative. It is built around the same eugeroic blueprint that made modafinil a favorite for focus and sustained alertness, with structural tweaks intended to modify its activity. Because the analog itself has not been formally studied, it is best understood as an experimental research chemical riding on the well-mapped pharmacology of its parent.

1 outlet

MAOI

Adarigiline

Adarigiline is an investigational monoamine oxidase B (MAO-B) inhibitor first described in a 2009 patent assigned to Helicon Therapeutics. It was never advanced to marketing and public pharmacology data remain sparse.

reference

Dopaminergic

Adrogolide

Adrogolide is a water-soluble prodrug that rapidly converts in plasma to A-86929, a highly selective full agonist at dopamine D1 receptors. It was investigated by Abbott Laboratories and DrugAbuse Sciences for Parkinson's disease and cocaine dependence but development was discontinued in 2001.

reference

MAOI

AGN-1135

AGN-1135 is the racemic mixture of rasagiline (the R-(+)-enantiomer) and its much less active S-(-)-enantiomer, TVP-1022. It is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor; nearly all of its MAO-B inhibiting activity comes from the rasagiline component, which was later developed and approved on its own for Parkinson's disease.

reference

Dopaminergic

Alentemol

Alentemol is an investigational compound described as a selective dopamine autoreceptor agonist that was studied as a potential antipsychotic. It was never marketed and published pharmacology data are limited.

reference

Phenethylamine

Alfetamine

An investigational phenethylamine studied briefly in the early 1970s as a possible antidepressant. Despite belonging to the broader amphetamine-related phenethylamine family, its pharmacology resembled tricyclic antidepressants rather than classic stimulant amphetamines.

reference

Nootropic

TAK-063

Balipodect (TAK-063) is a selective phosphodiesterase 10A (PDE10A) inhibitor developed by Takeda as a potential antipsychotic for schizophrenia. It has completed phase 2 proof-of-concept testing and, as of 2026, was acquired by Axsome Therapeutics for further development.

reference